Patents Assigned to Genentech
  • Publication number: 20200030443
    Abstract: The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., etoposide).
    Type: Application
    Filed: June 21, 2019
    Publication date: January 30, 2020
    Applicant: Genentech, Inc.
    Inventor: Ariel Lopez-Chavez
  • Patent number: 10544218
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Patent number: 10544215
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: John A. Flygare, Thomas H. Pillow, Brian Safina, Vishal Verma, BinQing Wei, William Denny, Anna Giddens, Ho Lee, Guo-Liang Lu, Christian Miller, Gordon Rewcastle, Moana Tercel, Muriel Bonnet
  • Patent number: 10544198
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang, Ganesh A. Kolumam, Wyne P. Lee
  • Publication number: 20200023063
    Abstract: The invention relates to use of non-surfactant compounds including, for example, polyoxyethylene (POE) sorbitans and polyethylene glycols (PEGs), for stabilizing protein-containing formulations and for the prevention of aggregation of proteins in such formulations.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Junyan JI, Jun LIU, Yuchang John WANG
  • Publication number: 20200024670
    Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Thomas E. Januario, David Shames
  • Publication number: 20200025775
    Abstract: Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 23, 2020
    Applicant: GENENTECH, INC.
    Inventors: Lauri Diehl, Mary Keir, Meina Tao Tang, Xiaohui Wei, Marna B. Williams
  • Publication number: 20200017601
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Sunil BHAKTA, Hans ERICKSON, Jagath R. JUNUTULA, Katherine KOZAK, Rachana OHRI, Thomas PILLOW
  • Publication number: 20200017469
    Abstract: The invention provides 4-piperidin-chroman-7-sulfonamide derivatives and salts thereof that are sodium channel modulators, as well as compositions containing such a compound or salt and therapeutic methods for using such a compound, salt, or composition.
    Type: Application
    Filed: March 22, 2018
    Publication date: January 16, 2020
    Applicant: GENENTECH, INC.
    Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Kwong Wah LAI
  • Publication number: 20200017579
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: May 23, 2019
    Publication date: January 16, 2020
    Applicants: AC Immune SA, Genentech, Inc.
    Inventors: Oskar Adolfsson, Isidro Hotzel, Danielle DiCara
  • Patent number: 10533058
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 14, 2020
    Assignees: Genentech Inc., Medimmune Limited
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
  • Patent number: 10532108
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 14, 2020
    Assignee: GENENTECH, INC.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Vishal Verma, Donglu Zhang
  • Publication number: 20200010420
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 9, 2020
    Applicants: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. GUNZNER-TOSTE, Daniel SUTHERLIN, Mark S. STANLEY, Liang BAO, Georgette M. CASTANEDO, Rebecca L. LALONDE, Shumei WANG, Mark E. REYNOLDS, Scott J. SAVAGE, Kimberly MALESKY, Michael S. DINA, Michael F.T. KOEHLER
  • Patent number: 10525137
    Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: January 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Brian Connolly, Lydia Hamburg, Emily Holz
  • Patent number: 10526285
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: January 7, 2020
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
  • Publication number: 20200002346
    Abstract: Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: September 5, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Po-wai YUEN, Emily J. HANAN
  • Publication number: 20200002340
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: September 3, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Brian SAFINA, Daniel SHORE, Jack TERRETT, Elisia VILLEMURE, Matthew VOLGRAF, Stuart WARD, Aijun LU, Robin LAROUCHE-GAUTHIER, Francis BEAUMIER, Martin DERY, Lea CONSTANTINEAU-FORGET, Chantal GRAND-MAITRE, Luce LEPISSIER
  • Publication number: 20200002331
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: CHEOL KEUN CHUNG, JIE XU, HANS IDING, KYLE CLAGG, MICHAEL DALZIEL, ALEC FETTES, FRANCIS GOSSELIN, NGIAP-KIE LIM, ANDREW MCCLORY, HAIMING ZHANG, PAROMA CHAKRAVARTY, KARTHIK NAGAPUDI, SARAH ROBINSON
  • Publication number: 20200002353
    Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
  • Publication number: 20200000780
    Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Timothy HEFFRON, Sushant MALHOTRA, BinQing WEI, Bryan CHAN, Lewis GAZZARD, Emanuela GANCIA, Michael LAINCHBURY, Andrew MADIN, Eileen SEWARD, Yonghan HU